Researchers at Dartmouth-Hitchcock Medical Center are part of a team working to develop the market’s first nasal spray COVID-19 vaccine. Dartmouth health officials said the vaccine does not need to be refrigerated or administered by a medical professional. “This vaccine could easily be distributed in developing regions of the world.Intranasal vaccines are used to protect against other viruses such as measles and rubella.”Unique in the field of novel coronavirus. Nonetheless, this vaccine sets a very successful precedent for the prevention of adenoviral respiratory disease. The research is being conducted in collaboration with Belgium-based viral vector maker National Institutes of Health and Exetera. DHMC is the sole research and development center for this vaccine, with clinical trials planned in the United States and Africa. China is developing an intranasal vaccine to be used as a booster dose, and other intranasal vaccines are in development. Dartmouth health officials said it was injectable. Although COVID-19 vaccines were developed rapidly, low- and lower-middle-income countries struggled to fully protect their populations during initial vaccine rollouts. The researchers said an intranasal vaccine could be easier to distribute than the oral infusions used worldwide to distribute polio vaccines. >> Watch recent New Hampshire COVID-19 coverage in the video player below.
Researchers at Dartmouth-Hitchcock Medical Center are part of a team working to develop the market’s first nasal spray COVID-19 vaccine.
Dartmouth health officials said the vaccine does not need to be refrigerated or administered by medical professionals, making it easier to distribute to developing regions of the world.
Intranasal vaccines are used to protect against other viruses such as measles and rubella.
“Although unique in the field of novel coronavirus, this vaccine has precedents that have been very successful in preventing adenoviral respiratory disease in the U.S. military,” said Dr. Peter Wright, an infectious disease and global health physician who is leading the effort. said.
The study is being conducted in collaboration with Belgium-based viral vector manufacturers National Institutes of Health and Exothera. DHMC is the sole research and development center for the vaccine, with clinical trials planned in the US and Africa.
China is developing a nasal vaccine to be used as a booster, and other nasal vaccines are under development.
Dartmouth health officials said an injectable COVID-19 vaccine was developed rapidly, but low- and lower-middle-income countries struggled to fully protect their populations during the initial rollout of the vaccine. Stated. The researchers said an intranasal vaccine could be easier to distribute than the oral infusion vaccine that is used to administer polio vaccines around the world.
>> Watch recent New Hampshire COVID-19 coverage in the video player below.
